Marie Louise (Marieke) De Bruin

Medicine & Life Sciences

1. Antidepressive Agents 25%
2. Biological Products 54%
3. Breast Neoplasms 70%
4. Cardiac Arrhythmias 54%
5. Chronic Obstructive Pulmonary Disease 22%
6. Cohort Studies 68%
7. Confidence Intervals 35%
8. Databases 69%
9. Decision Making 36%
10. Delivery of Health Care 19%
11. Drug-Related Side Effects and Adverse Reactions 68%
12. European Union 80%
13. Gastrointestinal Neoplasms 20%
14. General Practice 19%
15. Genetic Predisposition to Disease 25%
16. Heart Arrest 19%
17. Hip Fractures 22%
18. Hodgkin Disease 100%
19. Incidence 42%
20. Incretins 21%
21. Insulin 37%
22. Insulin Glargine 27%
23. Marketing 80%
24. Meta-Analysis 36%
25. Metformin 20%
26. Myocardial Infarction 26%
27. Neoplasms 27%
28. Netherlands 34%
29. Observational Studies 44%
30. Obstructive Lung Diseases 22%
31. Odds Ratio 24%
32. Out-of-Hospital Cardiac Arrest 21%
33. Pharmaceutical Preparations 77%
34. Pharmacovigilance 69%
35. Population 45%
36. Procarbazine 23%
37. Progressive Multifocal Leukoencephalopathy 23%
38. Radiation 27%
39. Radiation-Induced Neoplasms 38%
40. Radiotherapy 31%
41. Risk Assessment 25%
42. Rosiglitazone 32%
43. Safety 65%
44. Sudden Cardiac Death 21%
45. Survivors 33%
46. Systematic Reviews 33%
47. Therapeutics 24%
48. Type 2 Diabetes Mellitus 44%
49. Uncertainty 23%
50. Urinary Bladder Neoplasms 24%